Subscription banner for an ophthalmic newsletter
Maestro®: The Sinusoidal IOL

Maestro®: The Sinusoidal IOL

September 18, 2024

VSY Biotechnology to Complete Global Rollout of its Sinusoidal Vision Technology (SVT®) at ESCRS 2024 

This year's European Society of Cataract and Refractive Surgeons (ESCRS) 2024 kicked off with the highly anticipated third iNovation Day, which brought together the medical community and industry partners to discuss current and future trends shaping the field. 

All topics discussed showed a shift in the relationships among the key stakeholders. While patients are more and more informed and demanding, surgeons have an increasing role as communicators to identify the best solution for patient-specific requirements and their potential trade-offs. As the line between cataract and refractive surgery is blurred, there is a need to categorize the premium offer further to support easier clinical decision-making and to manage better patients’ expectations. Also, for presbyopia-correcting IOLs, the reimbursement landscape is likely to shift to more co-payment options for patients thanks to more health consciousness and long-term cost savings. Finally, there was an outlook on AI-based tools and how this can optimize ophthalmology the same way other medical disciplines already use it.

VSY Biotechnology’s Role at ESCRS 2024

VSY Biotechnology was a proud participant in the panel discussion “Managing Presbyopia: Keys to Sustainable Category Growth,” which addressed ongoing concerns surrounding presbyopia-correcting IOLs. Tanja Cotoaga, Global Marketing Manager at the company, emphasized that “At VSY Biotechnology, the patient is the cornerstone of everything we are doing. This is why we continuously strive to offer the most advanced solutions for visual acuity and contrast sensitivity across all distances and for nighttime vision. Our patented and unique Sinusoidal Vision Technology (SVT®), courtesy of its singular design, offers a specific diffractive pattern that allows for seamless vision and high contrast sensitivity - be it near, mid, or far distance – and in all light conditions.

VSY Biotechnology representative at Enova Maestro IOL System display - ESCRS 2024 Congress

Launch of Maestro®: The Sinusoidal IOL

During a breakfast meeting at ESCRS 2024, VSY Biotechnology introduced its new premium trifocal lens, Maestro®: The Sinusoidal IOL, which incorporates Sinusoidal Vision Technology (SVT®), as well as its new preloaded Extended Depth of Focus (EdoF) IOL, Advanced™, featuring the company's proprietary Light Tailoring Technology. “Our booth talk series offered each a deeper dive into both lenses based on experiences and clinical outcomes from Spain. One of our speakers highlighted that our Advanced™ lens qualifies as a real EdoF Lens instead of being just another monofocal-plus IOL. In our booth talks, we learned that Advanced™ can also be well-suited for critical patient profiles, such as those with stable keratoconus or post-LASIK corneas with superior aberrometry outcomes, as noted by Tanja Cotoaga. “So, we are driving further the requested standardization of lens categories to optimize visual outcomes and manage better patients’ expectations.”

The Advantages of Maestro®

The presentation on Maestro®: The Sinusoidal IOL highlighted that it combines the benefits of its unique trifocal lens design with innovative, 100% glistening-free hydrophobic material. Thanks to optimal light distribution and its impressive and maximum light transmission (93.5%) to the retina, it ensures high visual acuity and optimal contrast sensitivity in all light conditions. This makes it a standout solution in the premium trifocal lens market.

VSY Biotechnology booth at ophthalmology conference showcasing Enova Maestro IOL System

Sinusoidal Vision Technology (SVT®): A Game-Changer in Presbyopia Management 

“In our satellite symposium, we discussed to what extent our Sinusoidal Vision Technology (SVT®) can offer what it takes to finally master presbyopia. Whereas the ideal solution might not exist from a scientific and medical perspective, we though know that by launching Sinusoidal Vision Technology (SVT®), we are close to reaching the ultimate stage of lens design development. Tanja Cotoaga further noted that while the innovation cycle for IOLs is maturing, “Sinusoidal Vision Technology (SVT®) still allows us to differentiate VSY Biotechnology from the big players. As other big manufacturers are now following with fine adjustments, we feel that our Sinusoidal Vision Technology (SVT®) SVT® marks a milestone in the latest IOL technology.”

For more details on Maestro®, view the full product brochure here.